
    
      Participants are considered to have completed the study after Cycle 12. Amendment 4 (14 April
      2015) was done to allow participants on active treatment at the time the study was closed to
      enrollment to continue study treatment beyond Cycle 12 if deriving clinical benefit, at the
      Investigator's discretion.
    
  